168 related articles for article (PubMed ID: 2239935)
1. Bioavailability of iron in hemodialysis patients treated with erythropoietin: evidence for the inhibitory role of aluminum.
Donnelly SM; Ali MA; Churchill DN
Am J Kidney Dis; 1990 Nov; 16(5):447-51. PubMed ID: 2239935
[TBL] [Abstract][Full Text] [Related]
2. The role of aluminum in the functional iron deficiency of patients treated with erythropoietin: case report of clinical characteristics and response to treatment.
Donnelly SM; Smith EK
Am J Kidney Dis; 1990 Nov; 16(5):487-90. PubMed ID: 2239943
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin independence in chronic hemodialysis patients: clinical features, iron homeostasis and erythropoiesis.
Kuo CC; Lee CT; Chuang CH; Su Y; Chen JB
Clin Nephrol; 2005 Feb; 63(2):92-7. PubMed ID: 15730050
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability in optimizing response.
Rutherford CJ; Schneider TJ; Dempsey H; Kirn DH; Brugnara C; Goldberg MA
Am J Med; 1994 Feb; 96(2):139-45. PubMed ID: 8109598
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants.
Shannon KM; Keith JF; Mentzer WC; Ehrenkranz RA; Brown MS; Widness JA; Gleason CA; Bifano EM; Millard DD; Davis CB
Pediatrics; 1995 Jan; 95(1):1-8. PubMed ID: 7770284
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis.
Piazza V; Villa G; Galli F; Segagni S; Bovio G; Poggio F; Picardi L; Salvadeo A
Nephron; 1992; 61(1):54-7. PubMed ID: 1528341
[TBL] [Abstract][Full Text] [Related]
7. Assessment of iron status by erythrocyte ferritin in uremic patients with or without recombinant human erythropoietin therapy.
Caravaca F; Vagace JM; Aparicio A; Groiss J; Pizarro JL; Alonso N; Garcia MC; Arrobas M; Cubero J; Esparrago J
Am J Kidney Dis; 1992 Sep; 20(3):249-54. PubMed ID: 1519605
[TBL] [Abstract][Full Text] [Related]
8. Monitoring considerations in recombinant human erythropoietin therapy.
Ogden DA
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
[TBL] [Abstract][Full Text] [Related]
9. Postoperative intravenous iron used alone or in combination with low-dose erythropoietin is not effective for correction of anemia after cardiac surgery.
Madi-Jebara SN; Sleilaty GS; Achouh PE; Yazigi AG; Haddad FA; Hayek GM; Antakly MC; Jebara VA
J Cardiothorac Vasc Anesth; 2004 Feb; 18(1):59-63. PubMed ID: 14973801
[TBL] [Abstract][Full Text] [Related]
10. Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
Chiang WC; Tsai TJ; Chen YM; Lin SL; Hsieh BS
Clin Nephrol; 2002 Nov; 58(5):363-9. PubMed ID: 12425487
[TBL] [Abstract][Full Text] [Related]
11. Low dose desferrioxamine can improve erythropoiesis in iron-overload hemodialysis patients without side effects.
Lee CT; Liao SC; Hsu KT; Lam KK; Chen JB
Ren Fail; 1999 Nov; 21(6):665-73. PubMed ID: 10586429
[TBL] [Abstract][Full Text] [Related]
12. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
[TBL] [Abstract][Full Text] [Related]
13. [Influence of iron metabolism on the efficacy of r-HuEPO (recombinant human erythropoietin) treatment of anemia in children on hemodialysis].
Pela I; Lavoratti GC; Materassi M; Burgio G; Bartolozzi G
Pediatr Med Chir; 1991; 13(5):475-7. PubMed ID: 1788107
[TBL] [Abstract][Full Text] [Related]
14. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial.
Kleinman KS; Schweitzer SU; Perdue ST; Bleifer KH; Abels RI
Am J Kidney Dis; 1989 Dec; 14(6):486-95. PubMed ID: 2688405
[TBL] [Abstract][Full Text] [Related]
15. Circulating burst-forming-unit erythroid and the responsiveness to recombinant human erythropoietin in patients on regular hemodialytic treatment.
Brunati C; Cappellini MD; De Feo T; Stefanoni I; Civati G; Ballerini L; Fiorelli G; Minetti L
Nephron; 1992; 62(2):150-4. PubMed ID: 1436306
[TBL] [Abstract][Full Text] [Related]
16. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
[TBL] [Abstract][Full Text] [Related]
18. Effects of azathioprine on response of renal anaemia to subcutaneous recombinant human erythropoietin.
Howarth JE; Waters HM; Shanks D; Hyde K; Yin JA; Geary CG; Anastassiades E; Howarth D; Gokal R
J Clin Pathol; 1993 Jan; 46(1):41-4. PubMed ID: 8432886
[TBL] [Abstract][Full Text] [Related]
19. The effect of subcutaneous recombinant human erythropoietin (r-HuEPO) on anemia in cancer patients receiving platinum-based chemotherapy.
Malik IA; Khan ZK; Hakimali A; Sabih M; Rehman G
J Pak Med Assoc; 1998 May; 48(5):127-31. PubMed ID: 9813972
[TBL] [Abstract][Full Text] [Related]
20. Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis.
Zehnder C; Blumberg A
Clin Nephrol; 1989 Feb; 31(2):55-9. PubMed ID: 2920469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
